http://purl.org/np/RA7gbqitc-... RA7gbqitc-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-30T07:16:32.903Z

http://purl.org/np/RA7gbqitc-... RA7gbqitc-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

alendronate sodium tablets usp are a bisphosphonate indicated for treatment and prevention of osteoporosis in postmenopausal women 1 1 1 2 treatment to increase bone mass in men with osteoporosis 1 3 treatment of glucocorticoid induced osteoporosis 1 4 treatment of paget s disease of bone 1 5 limitations of use optimal duration of use has not been determined for patients at low risk for fracture consider drug discontinuation after 3 to 5 years of use 1 6 alendronate sodium tablets usp are indicated for the treatment of osteoporosis in postmenopausal women in postmenopausal women alendronate sodium tablets usp increase bone mass and reduces the incidence of fractures including those of the hip and spine vertebral compression fractures see clinical studies 14 1 alendronate sodium tablets usp are indicated for the prevention of postmenopausal osteoporosis see clinical studies 14 2 alendronate sodium tablets usp are indicated for treatment to increase bone mass in men with osteoporosis see clinical studies 14 3 alendronate sodium tablets usp are indicated for the treatment of glucocorticoid induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7 5 mg or greater of prednisone and who have low bone mineral density see clinical studies 14 4 alendronate sodium tablets usp are indicated for the treatment of paget s disease of bone in men and women treatment is indicated in patients with paget s disease of bone who have alkaline phosphatase at least two times the upper limit of normal or those who are symptomatic or those at risk for future complications from their disease see clinical studies 14 5 the optimal duration of use has not been determined the safety and effectiveness of alendronate sodium tablets usp for the treatment of osteoporosis are based on clinical data of four years duration all patients on bisphosphonate therapy should have the need for continued therapy re evaluated on a periodic basis patients at low risk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture re evaluated periodically

Leoni Bücken

2021-06-30T07:16:32.903Z

http://purl.org/np/RA7gbqitc-... RA7gbqitc-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_5408 DOID_5408

Leoni Bücken

2021-06-30T07:16:32.903Z

http://purl.org/np/RA7gbqitc-... RA7gbqitc-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-30T07:16:32.903Z

http://purl.org/np/RA7gbqitc-... RA7gbqitc-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00630 drugbank:DB00630

Leoni Bücken

2021-06-30T07:16:32.903Z

http://purl.org/np/RA7gbqitc-... RA7gbqitc-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-30T07:16:32.903Z

http://purl.org/np/RA7gbqitc-... RA7gbqitc-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-30T07:16:32.903Z

http://purl.org/np/RA7gbqitc-... RA7gbqitc-

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-06-30T07:16:32.903Z